Sirtex wins $1.3m Start grant
Thursday, 28 October, 2004
Sirtex (ASX: SRX) has been awarded a AUD$1.311 million R&D Start grant from AusIndustry to commercialise its Targeted Hyperthermia Therapy.
Targeted Hyperthermia Therapy uses the company's microsphere platform technology to deliver magnetic nanoparticles to tumours, followed by treatment with an alternating magnetic field to heat up the tumour causing death of the cancer cells.
The company has recently overcome some technical issues regarding the scale up of the treatment from animals to humans.
Personalised melanoma vaccine cuts risk of recurrence
Adding a personalised, mRNA-based cancer vaccine to standard immunotherapy after surgery for...
Research project to produce fish-free omega-3
SCU researchers are investigating how to grow omega-3-producing microorganisms more cheaply...
Biodegradable smart patch can detect and treat blood clots
Researchers have developed a biodegradable smart patch that detects pressure changes and releases...
